HIV(ヒト免疫不全ウイルス)治療法の世界市場予測・分析2019-2023

◆英語タイトル:HIV (Human Immunodeficiency Virus) Therapeutics Market by Type, Product, and Geography - Forecast and Analysis 2019-2023
◆商品コード:IRTNTR32179
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年10月31日
◆ページ数:175
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥270,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥324,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Technavio社の本調査レポートでは、HIV(ヒト免疫不全ウイルス)治療法の世界市場について調べ、HIV(ヒト免疫不全ウイルス)治療法の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、HIV(ヒト免疫不全ウイルス)治療法の市場規模をセグメンテーション別(種類別(併用療法、単剤療法)、製品別、)と地域別(グローバル)に分けて算出しました。Technavio社はHIV(ヒト免疫不全ウイルス)治療法の世界市場規模が2019-2023期間中に年平均2%成長すると予測しています。
・サマリー
・レポートの範囲
・HIV(ヒト免疫不全ウイルス)治療法の市場状況
・HIV(ヒト免疫不全ウイルス)治療法の市場規模
・HIV(ヒト免疫不全ウイルス)治療法の市場予測
・HIV(ヒト免疫不全ウイルス)治療法の世界環境:ファイブフォース分析
・市場セグメンテーション:種類別(併用療法、単剤療法)
・市場セグメンテーション:製品別
・HIV(ヒト免疫不全ウイルス)治療法の顧客状況
・主要地域別市場規模:グローバル
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

Global HIV (Human immunodeficiency Virus) Therapeutics Market: About this market
Technavio’s HIV therapeutics market analysis considers sales from both combination therapy and monotherapy types. Our report also finds the sales of HIV therapeutics in Asia, Europe, North America, and ROW. In 2018, the combination therapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as high efficiency in the treatment of HIV will play a vital role in the combination therapy segment to maintain its market position. Also, our global HIV therapeutics market report looks at factors such as the growing awareness about HIV and the increasing number of initiatives to end the HIV epidemic, increasing funding, and approval of drugs, and strong pipeline. However, social stigma associated with HIV infection, high cost of antiretroviral therapies, and rising drug resistance may hamper the growth of the HIV therapeutics industry over the forecast period.

Global HIV (Human immunodeficiency Virus) Therapeutics Market: Overview
Growing awareness about HIV and an increasing number of initiatives to end the HIV epidemic
Various government organizations around the world are focusing on creating awareness about the development of novel medicines for the treatment of HIV. As a result, they are producing numerous initiatives such as Let’s Stop HIV, Stop HIV, Start Talking, and Stop HIV Stigma. They are also supporting the public health response to the global HIV epidemic. Such initiatives and support are not only minimizing the annual incidence of HIV infection but also boosting the demand for HIV therapeutics among patients and healthcare units. Such factors will lead to the expansion of the global HIV therapeutics market at a CAGR of almost 2% during the forecast period.

Advances in diagnostic testing for HIV
A significant shift is observed from traditional laboratory testing for HIV, such as enzyme-linked immunosorbent assay (ELISA), saliva tests, and viral load test, to rapid point-of-care (POC) testing. POC HIV testing is the most accepted method. This method has been implemented to overcome some of the patient and provider barriers to routine screening. The preference for self-testing for HIV has been rapidly growing across developed countries. The home HIV test kit or HIV self-testing in a home setting marks the presence of HIV-1/2 antibodies or HIV-1 p24 antigen. The outcome of POC testing is improved by the development of sensors, microsystems, and low-cost imaging technologies. The market has also witnessed the development of mobile HIV diagnostic tools that revolutionize the detection of HIV in developing countries. Such advancements in diagnostic testing for HIV will have a positive impact on the overall market growth.
For the detailed list of factors that will drive the global HIV therapeutics market during the forecast period 2019-2023, click here.

Competitive Landscape
With the presence of a few significant players, the global HIV therapeutics market is moderately concentrated. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading HIV therapeutics manufacturers, that include AbbVie Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson & Johnson Services Inc., Lupin Ltd., Merck & Co. Inc., Mylan NV, Pfizer Inc., and Teva Pharmaceutical Industries Ltd.
Also, the HIV therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Combination therapy – Market size and forecast 2018-2023
• Monotherapy – Market size and forecast 2018-2023
• Market opportunity by type
PART 07: MARKET SEGMENTATION BY PRODUCT
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: MARKET TRENDS
• Advances in diagnostic testing for HIV
• R&D of regenerative therapies
• Increasing R&D of HIV vaccines
PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AbbVie Inc.
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Co.
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences Inc.
• GlaxoSmithKline Plc
• Johnson & Johnson Services Inc.
• Lupin Ltd.
• Merck & Co., Inc.
• Mylan NV
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
PART 15: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 16: EXPLORE TECHNAVIO


Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of the global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Type – Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Combination therapy – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Combination therapy – Year-over-year growth 2019-2023 (%)
Exhibit 22: Monotherapy – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Monotherapy – Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by type
Exhibit 25: Market segmentation by product: overview
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America – Year-over-year growth 2019-2023 (%)
Exhibit 31: Top 3 countries in North America
Exhibit 32: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in Europe
Exhibit 35: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Asia
Exhibit 38: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 39: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in ROW
Exhibit 41: Key leading countries
Exhibit 42: Market opportunity
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendors covered
Exhibit 47: Vendor classification
Exhibit 48: Market positioning of vendors
Exhibit 49: AbbVie Inc. – Vendor overview
Exhibit 50: AbbVie Inc. – Business segments
Exhibit 51: AbbVie Inc. – Organizational developments
Exhibit 52: AbbVie Inc. – Geographic focus
Exhibit 53: AbbVie Inc. – Key offerings
Exhibit 54: AbbVie Inc. – Key customers
Exhibit 55: Boehringer Ingelheim International GmbH – Vendor overview
Exhibit 56: Boehringer Ingelheim International GmbH – Business segments
Exhibit 57: Boehringer Ingelheim International GmbH – Organizational developments
Exhibit 58: Boehringer Ingelheim International GmbH – Geographic focus
Exhibit 59: Boehringer Ingelheim International GmbH – Segment focus
Exhibit 60: Boehringer Ingelheim International GmbH – Key offerings
Exhibit 61: Boehringer Ingelheim International GmbH – Key customers
Exhibit 62: Bristol-Myers Squibb Co. – Vendor overview
Exhibit 63: Bristol-Myers Squibb Co. – Business segments
Exhibit 64: Bristol-Myers Squibb Co. – Organizational developments
Exhibit 65: Bristol-Myers Squibb Co. – Geographic focus
Exhibit 66: Bristol-Myers Squibb Co. – Key offerings
Exhibit 67: Bristol-Myers Squibb Co. – Key customers
Exhibit 68: F. Hoffmann-La Roche Ltd. – Vendor overview
Exhibit 69: F. Hoffmann-La Roche Ltd. – Business segments
Exhibit 70: F. Hoffmann-La Roche Ltd. – Organizational developments
Exhibit 71: F. Hoffmann-La Roche Ltd. – Geographic focus
Exhibit 72: F. Hoffmann-La Roche Ltd. – Segment focus
Exhibit 73: F. Hoffmann-La Roche Ltd. – Key offerings
Exhibit 74: F. Hoffmann-La Roche Ltd. – Key customers
Exhibit 75: Gilead Sciences Inc. – Vendor overview
Exhibit 76: Gilead Sciences Inc. – Business segments
Exhibit 77: Gilead Sciences Inc. – Organizational developments
Exhibit 78: Gilead Sciences Inc. – Geographic focus
Exhibit 79: Gilead Sciences Inc. – Key offerings
Exhibit 80: Gilead Sciences Inc. – Key customers
Exhibit 81: GlaxoSmithKline Plc – Vendor overview
Exhibit 82: GlaxoSmithKline Plc – Business segments
Exhibit 83: GlaxoSmithKline Plc – Organizational developments
Exhibit 84: GlaxoSmithKline Plc – Geographic focus
Exhibit 85: GlaxoSmithKline Plc – Segment focus
Exhibit 86: GlaxoSmithKline Plc – Key offerings
Exhibit 87: GlaxoSmithKline Plc – Key customers
Exhibit 88: Johnson & Johnson Services, Inc. – Vendor overview
Exhibit 89: Johnson & Johnson Services, Inc. – Business segments
Exhibit 90: Johnson & Johnson Services, Inc. – Organizational developments
Exhibit 91: Johnson & Johnson Services, Inc. – Geographic focus
Exhibit 92: Johnson & Johnson Services, Inc. – Segment focus
Exhibit 93: Johnson & Johnson Services, Inc. – Key offerings
Exhibit 94: Johnson & Johnson Services, Inc. – Key customers
Exhibit 95: Lupin Ltd. – Vendor overview
Exhibit 96: Lupin Ltd. – Business segments
Exhibit 97: Lupin Ltd. – Organizational developments
Exhibit 98: Lupin Ltd. – Geographic focus
Exhibit 99: Lupin Ltd. – Key offerings
Exhibit 100: Lupin Ltd. – Key customers
Exhibit 101: Merck & Co. Inc. – Vendor overview
Exhibit 102: Merck & Co. Inc. – Business segments
Exhibit 103: Merck & Co. Inc. – Organizational developments
Exhibit 104: Merck & Co. Inc. – Geographic focus
Exhibit 105: Merck & Co. Inc. – Segment focus
Exhibit 106: Merck & Co. Inc. – Key offerings
Exhibit 107: Merck & Co. Inc. – Key customers
Exhibit 108: Mylan NV – Vendor overview
Exhibit 109: Mylan NV – Product segments
Exhibit 110: Mylan NV – Organizational developments
Exhibit 111: Mylan NV – Geographic focus
Exhibit 112: Mylan NV – Segment focus
Exhibit 113: Mylan NV – Key offerings
Exhibit 114: Mylan NV – Key customers
Exhibit 115: Pfizer Inc. – Vendor overview
Exhibit 116: Pfizer Inc. – Business segments
Exhibit 117: Pfizer Inc. – Organizational developments
Exhibit 118: Pfizer Inc. – Geographic focus
Exhibit 119: Pfizer Inc. – Segment focus
Exhibit 120: Pfizer Inc. – Key offerings
Exhibit 121: Pfizer Inc. – Key customers
Exhibit 122: Teva Pharmaceutical Industries Ltd. – Vendor overview
Exhibit 123: Teva Pharmaceutical Industries Ltd. – Business segments
Exhibit 124: Teva Pharmaceutical Industries Ltd. – Organizational developments
Exhibit 125: Teva Pharmaceutical Industries Ltd. – Segment focus
Exhibit 126: Teva Pharmaceutical Industries Ltd. – Key offerings
Exhibit 127: Teva Pharmaceutical Industries Ltd. – Key customers
Exhibit 128: Validation techniques employed for market sizing
Exhibit 129: Definition of market positioning of vendors



【掲載企業】

AbbVie Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson & Johnson Services Inc., Lupin Ltd., Merck & Co. Inc., Mylan NV, Pfizer Inc., and Teva Pharmaceutical Industries Ltd.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[HIV(ヒト免疫不全ウイルス)治療法の世界市場予測・分析2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆